CAMBRIDGE, Mass., June 13, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback